The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Digging into biopharma’s big buyout areas
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Biding your time buying is becoming costly
Companies with late-stage assets have been attracting ever higher price tags over the past five years, Evaluate Vantage finds.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
The year of the small buyout
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
In a quiet year for takeouts, who was buying?
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
